Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gw-406381. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 17/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gw-406381 SCHEMBL7509921 | 0.99 | PTGS2 (0.98) | PTGS2PTGS1 | |
| SCHEMBL5458900 | 0.90 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL4511717 | 0.90 | PTGS2 (0.81) | PTGS2PTGS1 | |
| SCHEMBL5446848 | 0.88 | PTGS1 (1.00) | PTGS2PTGS1 | |
| SCHEMBL27481285 | 0.85 | PTGS2 (1.00) | PTGS2PTGS1 | |
| Alcohol SCHEMBL3654962 | 0.84 | PTGS2 (0.89) | PTGS2PTGS1 | |
| SCHEMBL5447762 | 0.84 | PTGS1 (0.77) | PTGS2PTGS1 | |
| SCHEMBL5448511 | 0.83 | PTGS2 (0.82) | PTGS2PTGS1 | |
| SCHEMBL7693623 | 0.83 | PTGS2 (0.70) | PTGS2PTGS1 | |
| SCHEMBL5368685 | 0.78 | PTGS2 (0.64) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 571 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144740-A1 | SYNERGISTIC COMBINATIONS OF VR-1 ANTAGONISTS AND COX-2 INHIBITORS | NOVARTIS AG (CH) | 2010-06-10 | — | — | US | claimed |
| EP-2023718-A2 | CREATINE-LIGAND COMPOUNDS AND METHODS OF USE THEREOF | Avicena Group, Inc. (US) | 2009-02-18 | — | — | EP | claimed |
| WO-2008137137-A1 | CREATINE ASCORBYL DERIVATIVES AND METHODS OF USE THEREOF | AVICENA GROUP, INC. (US) | 2008-11-13 | — | — | WO | claimed |
| WO-2007133731-A2 | CREATINE-LIGAND COMPOUNDS AND METHODS OF USE THEREOF | AVICENA GROUP, INC. (US) | 2007-11-22 | — | — | WO | claimed |
| US-20070270428-A1 | Use of Cyclooxygenase-2 Inhibitors for the Treatment of Depressive Disorders | GLAXO GROUP LIMITED (GB) | 2007-11-22 | — | — | US | claimed |
| US-20070184109-A1 | Compositions comprising triptans and nsaids | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | claimed |
| US-20070142411-A1 | Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | claimed |
| EP-1259239-B1 | USE OF 2-(4-ETHOXY-PHENYL)-3-(4-METHANESULFONYL-PHENYL)-PYRAZOLO[1,5-b]PYRIDAZINE FOR THE TREATMENT OF NON-ULCERATIVE DYSPEPSIA | GLAXO GROUP LTD (GB) | 2007-03-28 | — | — | EP | claimed |
| EP-1687000-A2 | USE OF CYCLOOXYGENASE-2 INHIBITORS FOR THE TREATMENT OF DEPRESSIVE DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-08-09 | — | — | EP | claimed |
| EP-1687001-A2 | USE OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-08-09 | — | — | EP | claimed |
| EP-1239879-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-09-18 | — | — | EP | claimed |
| US-6451794-B1 | 2,3-Diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2(COX-2) inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-09-17 | — | — | US | claimed |
| EP-1235576-A2 | COMBINATIONS OF SUMATRIPTAN OR NARATRIPTAN WITH CYCLOOXYGENASE II INHIBITOR | GLAXO GROUP LIMITED (GB) | 2002-09-04 | — | — | EP | claimed |
| WO-2001056573-A1 | USE OF COX-2 INHIBITORS AS GASTROPROKINETICS | GLAXO GROUP LIMITED (GB) | 2001-08-09 | — | — | WO | claimed |
| WO-2001056555-A2 | USE OF COX-2 INHIBITORS FOR THE TREATMENT OF CONSTIPATION | GLAXO GROUP LIMITED (GB) | 2001-08-09 | — | — | WO | claimed |
| WO-2001046194-A2 | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-B]PYRIDAZINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | claimed |
| WO-2001045683-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | claimed |
| WO-2001041749-A2 | COMBINATIONS OF SUMATRIPTAN OR NARATRIPTAN WITH CYCLOOXYGENASE IIINHIBITOR | GLAXO GROUP LIMITED (GB) | 2001-06-14 | — | — | WO | claimed |
| EP-1032575-A1 | 2,3-DIARYL-PYRAZOLO(1,5-B)PYRIDAZINES DERIVATIVES, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-09-06 | — | — | EP | claimed |
| WO-1999012930-A1 | 2,3-DIARYL-PYRAZOLO[1,5-B]PYRIDAZINES DERIVATIVES, THEIR PREPA RATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-03-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270428-A1 | Use of Cyclooxygenase-2 Inhibitors for the Treatment of Depressive Disorders | TPH2, PTGS2, PTGES2 | PTGS2 2/4885PTGS1 13/4885 |
| US-20100144740-A1 | SYNERGISTIC COMBINATIONS OF VR-1 ANTAGONISTS AND COX-2 INHIBITORS | TRPV2, TRPV1, TRPV3 | PTGS2 37/4885PTGS1 27/4885 |
| US-20070142411-A1 | Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders | PTGES2, PTGER2, PTGDR2 | PTGS2 5/4885PTGS1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.